Stockreport

Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia

Esperion Therapeutics, Inc.  (ESPR) 
Last esperion therapeutics, inc. earnings: 2/27 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: investor.esperion.com
PDF – Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLET [Read more]